NO940322D0 - 1,3-oksatiolan-nukleosidanaloger - Google Patents

1,3-oksatiolan-nukleosidanaloger

Info

Publication number
NO940322D0
NO940322D0 NO940322A NO940322A NO940322D0 NO 940322 D0 NO940322 D0 NO 940322D0 NO 940322 A NO940322 A NO 940322A NO 940322 A NO940322 A NO 940322A NO 940322 D0 NO940322 D0 NO 940322D0
Authority
NO
Norway
Prior art keywords
nucleoside analogues
oxathiolane nucleoside
oxathiolane
analogues
nucleoside
Prior art date
Application number
NO940322A
Other languages
English (en)
Other versions
NO940322L (no
NO300842B1 (no
Inventor
Gervais Dionne
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10699340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO940322(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of NO940322D0 publication Critical patent/NO940322D0/no
Publication of NO940322L publication Critical patent/NO940322L/no
Publication of NO300842B1 publication Critical patent/NO300842B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/38—Nucleosides
    • C12P19/40—Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/001—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by metabolizing one of the enantiomers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO940322A 1991-08-01 1994-01-31 1,3-oksatiolan-nukleosidanaloger NO300842B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919116601A GB9116601D0 (en) 1991-08-01 1991-08-01 1,3-oxathiolane nucleoside analogues
PCT/CA1992/000321 WO1993003027A1 (en) 1991-08-01 1992-07-24 1,3-oxathiolane nucleoside analogues

Publications (3)

Publication Number Publication Date
NO940322D0 true NO940322D0 (no) 1994-01-31
NO940322L NO940322L (no) 1994-03-21
NO300842B1 NO300842B1 (no) 1997-08-04

Family

ID=10699340

Family Applications (3)

Application Number Title Priority Date Filing Date
NO940322A NO300842B1 (no) 1991-08-01 1994-01-31 1,3-oksatiolan-nukleosidanaloger
NO2005017C NO2005017I2 (no) 1991-08-01 2005-08-19 1,3-Oksatiolan-nukleosidanaloger
NO2008009C NO2008009I1 (no) 1991-08-01 2008-06-12 Emtricitabine i kombinasjon med tenofovir disproksil, spesielt fumaratet derav, samt efavirenz

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2005017C NO2005017I2 (no) 1991-08-01 2005-08-19 1,3-Oksatiolan-nukleosidanaloger
NO2008009C NO2008009I1 (no) 1991-08-01 2008-06-12 Emtricitabine i kombinasjon med tenofovir disproksil, spesielt fumaratet derav, samt efavirenz

Country Status (41)

Country Link
US (2) US5538975A (no)
EP (2) EP1155695B1 (no)
JP (1) JP2960778B2 (no)
KR (1) KR100242454B1 (no)
CN (5) CN1034810C (no)
AP (1) AP321A (no)
AT (2) ATE227720T1 (no)
AU (1) AU659668B2 (no)
BG (1) BG61693B1 (no)
CA (2) CA2114221C (no)
CZ (1) CZ283765B6 (no)
DE (2) DE69232845T2 (no)
DK (2) DK1155695T3 (no)
EE (1) EE03002B1 (no)
EG (1) EG20193A (no)
ES (2) ES2335968T3 (no)
FI (1) FI940435A (no)
GB (1) GB9116601D0 (no)
GE (1) GEP20002094B (no)
HK (2) HK1008672A1 (no)
HN (1) HN1997000118A (no)
HU (2) HUT70030A (no)
IL (1) IL102616A (no)
MA (1) MA22919A1 (no)
MD (1) MD1434C2 (no)
MX (1) MX9204474A (no)
NO (3) NO300842B1 (no)
NZ (1) NZ243637A (no)
OA (1) OA09883A (no)
PH (1) PH30983A (no)
PT (2) PT526253E (no)
RS (1) RS49993B (no)
RU (1) RU2126405C1 (no)
SG (1) SG68541A1 (no)
SK (1) SK280131B6 (no)
TJ (1) TJ244R3 (no)
TN (1) TNSN92070A1 (no)
TW (2) TW366347B (no)
WO (1) WO1993003027A1 (no)
YU (1) YU49259B (no)
ZA (1) ZA925668B (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6346627B1 (en) * 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
CA2637774C (en) * 1993-09-10 2011-07-19 Emory University Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
GB9506644D0 (en) * 1995-03-31 1995-05-24 Wellcome Found Preparation of nucleoside analogues
WO1996040164A1 (en) 1995-06-07 1996-12-19 Emory University Nucleosides with anti-hepatitis b virus activity
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
EP0970078B1 (en) * 1997-03-19 2004-05-19 Emory University Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
WO1998044913A2 (en) 1997-04-07 1998-10-15 Triangle Pharmaceuticals, Inc. Compositions containing mkc-442 in combination with other antiviral agents
EP1104415B1 (en) 1998-08-12 2004-11-10 Gilead Sciences, Inc. Method of manufacture of 1,3-oxathiolane nucleosides
US6979561B1 (en) * 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
CN1891221A (zh) 1998-11-02 2007-01-10 三角药物公司 对乙型肝炎病毒的联合治疗
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
AU2001249564A1 (en) 2000-03-29 2001-10-08 Cornell Research Foundation Inc. Method of treating hepatitis delta viral infection
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
ATE383355T1 (de) * 2001-03-01 2008-01-15 Abbott Lab Polymorph und andere kristallinische formen von zusammen-ftc
AU2008202336B2 (en) * 2001-03-01 2011-11-10 Abbvie Inc. Polymorphic and other crystalline forms of cis-FTC
WO2003051298A2 (en) * 2001-12-14 2003-06-26 Pharmasset Ltd. Preparation of intermediates useful in the synthesis of antiviral nucleosides
AU2004206827A1 (en) 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
ITMI20030578A1 (it) 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN100360528C (zh) * 2005-08-31 2008-01-09 四川大学 4-氨基-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基)-2(1h)-嘧啶酮的制备方法
WO2007077505A2 (en) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
EP2376514A2 (en) * 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
NZ593648A (en) * 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
DK2414507T3 (da) * 2009-04-03 2014-08-25 Medical Res Council Mutanter af aktiveringsinduceret cytidin-deaminase (aid) og til anvendelsesfremgangsmåder
EP2377862A1 (en) 2010-03-29 2011-10-19 Esteve Química, S.A. Process for obtaining emtricitabine
KR101715981B1 (ko) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 뉴클레오사이드 포스포르아미데이트
AU2012365627B2 (en) 2012-01-10 2017-05-25 C.C.Jensen A/S Method and system for cleaning degraded oil
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
DE2950317A1 (de) * 1979-12-14 1981-06-19 Agfa-Gevaert Ag, 5090 Leverkusen Elektrothermographische vorrichtung
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
HU226137B1 (en) * 1989-02-08 2008-05-28 Shire Canada Inc Process for preparing substituted 1,3-oxathiolanes with antiviral properties
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
WO1992010496A1 (en) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
EP1142891B1 (en) * 1991-03-06 2007-05-02 Emory University Salts and amides of (-)cis 5-Fluoro-2'-deoxy-3'-thiacytidine useful for the treatment of hepatitis B
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues

Also Published As

Publication number Publication date
CA2682254C (en) 2012-02-21
BG61693B1 (bg) 1998-03-31
GB9116601D0 (en) 1991-09-18
CN101074228A (zh) 2007-11-21
NO2005017I1 (no) 2005-09-05
NO940322L (no) 1994-03-21
OA09883A (en) 1994-09-15
RS49993B (sr) 2008-09-29
BG98616A (bg) 1995-03-31
RU2126405C1 (ru) 1999-02-20
HU9400285D0 (en) 1994-05-30
SK10494A3 (en) 1994-12-07
AP9200414A0 (en) 1992-07-31
DE69232845D1 (de) 2002-12-19
US5538975A (en) 1996-07-23
GEP20002094B (en) 2000-05-10
FI940435A0 (fi) 1994-01-28
HU211333A9 (en) 1995-11-28
PT1155695E (pt) 2010-02-02
CZ283765B6 (cs) 1998-06-17
ZA925668B (en) 1993-04-28
TW366347B (en) 1999-08-11
JPH07500317A (ja) 1995-01-12
ATE227720T1 (de) 2002-11-15
MA22919A1 (fr) 1993-04-01
EE03002B1 (et) 1997-06-16
CN100542535C (zh) 2009-09-23
TJ244R3 (en) 1999-11-24
SK280131B6 (sk) 1999-08-06
CZ20394A3 (en) 1994-07-13
MD950114A (en) 1996-06-28
CA2114221A1 (en) 1993-02-18
NZ243637A (en) 1995-03-28
EP0526253A1 (en) 1993-02-03
YU72303A (sh) 2006-05-25
YU49259B (sh) 2004-12-31
NO300842B1 (no) 1997-08-04
WO1993003027A1 (en) 1993-02-18
FI940435A (fi) 1994-01-28
US5618820A (en) 1997-04-08
NO2008009I1 (no) 2008-06-30
SG68541A1 (en) 1999-11-16
KR100242454B1 (ko) 2000-03-02
CN1302612A (zh) 2001-07-11
DK0526253T3 (da) 2003-03-17
EP0526253B1 (en) 2002-11-13
CN101066970A (zh) 2007-11-07
TNSN92070A1 (fr) 1993-06-08
DE69233776D1 (de) 2009-12-31
CN1070191A (zh) 1993-03-24
PH30983A (en) 1997-12-23
EP1155695A1 (en) 2001-11-21
EG20193A (en) 1997-10-30
MX9204474A (es) 1993-12-01
DE69232845T2 (de) 2003-04-24
AU2340892A (en) 1993-03-02
ATE448787T1 (de) 2009-12-15
HK1008672A1 (en) 1999-05-14
AP321A (en) 1994-02-28
CA2682254A1 (en) 1993-02-18
CN1074924C (zh) 2001-11-21
HN1997000118A (es) 1999-11-12
CA2114221C (en) 2009-12-22
DK1155695T3 (da) 2010-04-06
EP1155695B1 (en) 2009-11-18
PT526253E (pt) 2003-03-31
CN1034810C (zh) 1997-05-07
HK1038189A1 (en) 2002-03-08
MD1434B2 (en) 2000-03-31
YU74992A (sh) 1995-12-04
TWI232217B (en) 2005-05-11
HUT70030A (en) 1995-09-28
AU659668B2 (en) 1995-05-25
IL102616A0 (en) 1993-01-14
ES2186667T3 (es) 2003-05-16
JP2960778B2 (ja) 1999-10-12
NO2005017I2 (no) 2007-10-01
MD1434C2 (ro) 2000-12-31
CN1132073A (zh) 1996-10-02
IL102616A (en) 1996-10-31
ES2335968T3 (es) 2010-04-07

Similar Documents

Publication Publication Date Title
NO2005017I2 (no) 1,3-Oksatiolan-nukleosidanaloger
OA09559A (fr) 1,3-oxathiolane nucleoside analogues.
NL960025I1 (nl) Gesubstitueerde 1,3-oxathiolanen met antivirale activiteit.
DK23489A (da) Nucleosidderivater
FI893948A (fi) Antiviral behandlingsfoerfarande.
DE68918711D1 (de) Reinigungsmittel.
NO912804L (no) Purinderivater.
MX9102794A (es) Analogos de carbaciclina.
DK95791D0 (da) Nucleosidanaloge
DE68922683D1 (de) Handwebstuhl.
BA96098A (bs) 1,3-Oksatiolanski nukleozidni analozi
FI923542A (fi) Faestanordning foer klingor, isynnerhet i bestrykningsmaskiner
NO933064L (no) Hetero-antracyklin-antitumor-analoger
DE68914451D1 (de) Mundversorgungsmittel.
DE69002365D1 (de) Antivirale zusammensetzung.
NO911965L (no) Nukleosid-analoger.
NO934541D0 (no) LHRH analoger
FI895480A0 (fi) Styv takkonstruktion.
FI880573A0 (fi) Foerankringssidoanslag foer doerr.

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: TRUVADA-EMTRICITABENE; NAT. REG. NO/DATE: NO , EU/1/04/305/001/NO 20050307; FIRST REG. NO/DATE: EU , EU/1/04/305/001 20050221

Spc suppl protection certif: 2005017

Filing date: 20050819

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: TRUVADA-EMTRICITABENE; NAT. REG. NO/DATE: NO , EU/1/04/305/001/NO 20050307; FIRST REG. NO/DATE: EU , EU/1/04/305/001 20050221

Spc suppl protection certif: 2005017

Filing date: 20050819

Extension date: 20170724

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: ATRIPLA; NAT. REG. NO/DATE: C (2007) 6572 20071213; FIRST REG. NO/DATE: EU , C (2007) 6572 20071213

Spc suppl protection certif: 2008009

Filing date: 20080612

MK1K Patent expired